Travere Therapeutics, Inc. (TVTX) Q2 FY26 Earnings Call

Filspari delivered strong launch momentum, but management cautioned against extrapolating the initial FSGS quarter.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Length51 minutes
EPS$-0.37

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q1 FY26

All TVTX earnings ยท Back to TVTX overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.